The mechanisms by which gammaherpesviruses maintain latency are unclear. Here we used a murine gammaherpesvirus model to show that previously uninfected B cells in immunocompetent mice can acquire virus during latency. In vivo depletion of T cells allowed viral reactivation, as measured by increased viral loads, but not enhanced transfer of virus to new cells. In the absence of both immune T cells and antibody following the transfer of latently infected cells into naïve animals, there was robust infection of new B cells. These data confirm that both T cells and antibody contribute to the control of gammaherpesvirus latency, reactivation, and spread.
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The hallmark of herpesvirus (HV) infections is the establishment of latency, a lifelong condition characterized by persistent viral genome maintenance and restricted, low-level viral gene expression. The ability to reactivate from latency, reenter the lytic life cycle, and generate infectious virions is responsible for many of the secondary pathological consequences of HV infections, including autoimmunity, cancer, immunoproliferative disorders, recrudescent skin lesions, and transplant rejection (15, 19 ). An unresolved issue in the field of herpesvirology is how latent infections are maintained in the host over time. In the case of alphaherpesvirus (␣HV) latency, the viral genomes reside in nonreplicating cells such as neurons, and so latency is likely propagated by the mere survival of latently infected cells, with periodic de novo infections following reactivation events. ␤HV and ␥HV infections are different, as they establish latency in immune system cells, which, unlike neurons, not only can proliferate but also can express high levels of major histocompatibility complex (MHC) class I and are targets for T cell immunity. Since long-term latency persists even in the presence of functional virus-specific immunity, it is crucial to understand how viral latency is propagated in an immunocompetent host in order to develop rational strategies to control ␥HV infections.
Mechanisms for ␥HV latency persistence include viral immune evasion strategies; proliferation of latently infected B cells, in which latent viral episomes are replicated and transferred to the daughter cells; direct cell-to-cell transfer of infectious virus to naïve cells, in the absence of cell-free virus; and asymptomatic shedding of lytic virus, leading to the infection of new B cells. There is evidence in the literature for each of these mechanisms. For example, Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) protein is associated with driving the proliferation of infected B cells (8) . Furthermore, it has been shown that efficient EBV infection of epithelial cell lines requires cell-to-cell contact with virally infected cells in cocultures (3, 10) , a process that is refractory to inhibition by blocking antibodies (Abs), suggesting that cell-free virus is not required for infection (22) . In one study, long-term valacyclovir treatment did not affect the number of EBV DNA copies per B cell but did reduce the frequency of latently infected B cells, which is consistent with roles for both lytic viral replication and infected B cell half-life in maintaining viral loads during latency (9) . There is also evidence for asymptomatic EBV shedding (17) , and asymptomatic shedding has been noted in individuals infected with Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) (2, 16) . Ganciclovir treatment of KSHVseropositive HIV-infected patients versus placebo treatment resulted in reduced occurrences of KS indicative of a requirement for lytic replication in the etiology of KS, since ganciclovir does not inhibit latent virus (13) . Additionally, in vitro evidence suggests that latent KSHV genomes are inefficiently maintained during tumorigenesis and that KSHV may consequently require periodic lytic replication to perpetuate viral latency (6) . Thus, it is likely that gammaherpesvirus (␥HV) latency in infected humans is perpetuated by a combination of infected cell proliferation and periodic de novo infections after reactivation. EBV and KSHV infections are highly species specific, however, making in vivo mechanistic studies of viral latency very difficult. Therefore, we took advantage of a wellcharacterized small-animal model-intranasal infection of C57BL/6 mice with murine gammaherpesvirus-68 (␥HV68), a rodent pathogen closely related to EBV and KSHV (25)-to experimentally determine whether uninfected B cells could acquire virus during latency and to elucidate the roles of humoral and cellular immunity in the control of viral latency.
Spread of virus to naïve B cells during latency in immune mice. To generate a population of uninfected B cells that could be tracked during latency, we intraperitoneally treated latently infected mice with 0.6 mg of the chemotherapeutic bone marrow ablation agent busulfan (Busulfex; Otsuka America Pharmaceuticals), followed by lymphocyte reconstitution with 2 ϫ 10 7 bone marrow cells from naïve congenic mice (Fig. 1A) . By selectively depleting cells of the bone marrow, busulfan treatment allows the establishment of partial hematopoietic chime- rism without irradiation while leaving peripheral immunity largely intact; this approach has been used previously in studies of mice undergoing persistent viral infections (11, 21, 24) . Busulfan treatment alone, without congenic bone marrow reconstitution, resulted in a decrease in the total numbers of splenocytes (Fig. 1B) and a decrease in the percentages of splenic CD19
ϩ B cells but not of CD4 ϩ or CD8 ϩ T cells (Fig.  1C) . Importantly, latent viral loads in B cells sorted from the spleen were similar 1 week after busulfan or phosphate-buffered saline (PBS) control treatment, as measured by real-time PCR (Fig. 1D) (23) , demonstrating that busulfan treatment did not disrupt the viral loads of latently infected mice. This was probably a result of the low frequency of infected B cells being largely unaffected by the relatively slight decrease in B cell numbers. After busulfan treatment and reconstitution with congenic bone marrow, we observed considerable chimerism by 5 weeks, with the largest proportion of donor-derived lymphoid cells in the CD19 ϩ B cell compartment, likely because the donor-derived T cells required maturation in the thymus before entrance into the periphery (Fig. 1E) . Although the results showing the extent of chimerism differed among individual mice, most mice exhibited at least 50% chimerism in all lymphocyte subsets by 8 weeks after reconstitution (data not shown). Both antiviral antibody and T cell responses have been shown to be important for controlling infection and preventing viral recrudescence during ␥HV68 latency (1, 12), so to ensure that the partial bone marrow chimeras maintained virus-specific immunity, we measured the amount of antiviral IgG antibody by an enzyme-linked immunosorbent assay (ELISA) (Fig. 1F ) and the percentages of host CD8 ϩ T cells in the spleen specific for two immunodominant epitopes (ORF6 487-495 /D b and ORF61 524-531 /K b ) by tetramer staining (Fig. 1G) . Neither humoral nor cellular antiviral immunity was impaired following busulfan treatment and reconstitution.
The donor-derived B cells in the resulting partial bone marrow chimeras were initially uninfected, so any detectable virus they acquired was a direct consequence of de novo infection. Therefore, we sorted B cells from chimeras on host or donor congenic markers ( Fig. 2A) and measured viral genomic DNA in host and donor cells after 4, 7, or 20 to 23 weeks of reconstitution. Although we failed to detect viral DNA in donor B cells at 4 weeks, viral DNA was detectable in donor B cells in 2 out of 5 mice (40%) at 7 weeks and 6 out of 12 mice (50%) at 20 to 23 weeks (Fig. 2B) . These data conclusively demonstrate that naïve B cells can progressively acquire virus during ␥HV68 latency in immunocompetent mice.
Robust infection of donor-derived B cells following reactivation.
To investigate whether infection of naïve B cells could be enhanced in the absence of host cellular immunity, we first established partial mixed bone marrow chimeras by the use of host Thy1.2 ϩ mice and donor Thy1.1 ϩ mice and then depleted host T cells by treating the chimeras intraperitoneally with 250 g of anti-Thy1.2 monoclonal Ab (MAb) (30H12) every 3 days for 12 days (Fig. 3A) . This procedure substantially reduced host T cell numbers (Fig. 3B) and resulted in an impact on viral control, as evidenced by a robust increase in viral genome copy numbers in donor-derived B cells (Fig. 3C) , suggesting a critical role for T cells in maintaining ␥HV68 latency. There was a less dramatic effect of anti-Thy1.2 treatment on viral DNA in the host B cells-although there was a trend toward increased genome copies, the difference was not statistically significant (P ϭ 0.1259 [Student's t test]). This was most likely due to complications stemming from the range of viral DNA numbers in the host B cells coupled with our inability to measure DNA changes within individual mice. Alternatively, it could have been the result of host B cells providing the viral DNA that accumulated in the donor B cells, of host B cells being less sensitive to reactivation stimuli, as ex vivo reactivation efficiency declines over time (26) , or of host B cells being less susceptible to de novo infection, since they would include memory B cells and plasma cells but the donor B cell population would largely be composed of naïve and germinal center B cells (4, 20) .
The increase in viral genome numbers in the donor-derived B cells after anti-Thy1.2 treatment could have been due to DNA replication within already-infected cells or to de novo infection of naïve B cells by virus reactivating from host cells or to a combination of the two. We investigated whether the increase in viral DNA numbers after anti-Thy1. fected B cells would indicate that previously uninfected cells had acquired viral DNA during the anti-Thy1.2 treatment period. We observed a trend toward increased copy numbers in both the host and donor B cells, but the frequency of infected host B cells did not change following anti-Thy1.2 MAb treatment, and the frequency of infected donor B cells remained very low-below 1 in 4 ϫ 10 4 cells, our limit of detection for this particular assay (Fig. 3D) . Because anti-Thy1.2 MAbtreated mice remain antibody sufficient (Fig. 1F) , these data are consistent with previous findings reported from our laboratory indicating that virus-specific antibody is important for controlling viral recrudescence during latency (12) . In addition, we failed to detect infectious virus in the spleens or lungs of chimeric mice by a plaque assay performed after anti-Thy1.2 MAb treatment (data not shown). These data support the hypothesis that the majority of reactivation observed in the absence of T cells is due to robust viral genome replication within already infected cells and not to widespread infection of new B cells, though it is likely that some de novo infection does occur during reactivation.
Latently infected B cells reactivate efficiently in the absence of immunosurveillance. To confirm that latent virus efficiently reactivates in the complete absence of immune protection, we adoptively transferred graded numbers of purified B cells from latently infected mice (30 and 60 days postinfection [p.i.]) into naïve congenic hosts (Fig. 4A) . Reactivation, as indicated by an increase in genome copy numbers in host splenic B cells 30 days after transfer, occurred upon transfer of as few as 4.5 ϫ 10 4 cells from mice 30 days postinfection (Fig. 4B) . The numbers of transferred cells required for infection of the host corresponded to the frequency of latently infected cells present at the two time points-ϳ1 in 1.5 ϫ 10 3 in the 30-day mice as determined by LDA/PCR analysis of the pool of transferred cells (a maximum of ϳ300 latently infected cells transferred; data not shown) and ϳ1 in 5 ϫ 10 4 in the 60-day mice (a maximum of ϳ9 latently infected cells transferred; data not shown). Importantly, the in vivo reactivation efficiencies of the latently infected cells were comparable at 30 and 60 days p.i., in contrast to the reactivation efficiency seen in vitro, which has been shown to drop dramatically after 30 days p.i. (26) . Thus, transferring latently infected B cells into naïve recipient mice (which lack specific antiviral immunity) allows virus reactivation in the donor B cells and leads to de novo infection of host B cells, confirming clinical observations of virus-seronegative patients becoming seropositive after organ transplant (7) . Stimulation of latently infected B cells by treatment with antiIg/anti-CD40 antibodies or various Toll-like receptor ligands has been demonstrated to induce ␥HV68 reactivation from latency (5, 14, 18) , suggesting that inadvertent B cell stimulation during the transfer process could facilitate virus reactivation. However, the kinetics of reactivation after transfer argued against the likelihood that lytic virus or reactivating B cells were transferred, as we were unable to detect lytic virus in the spleens and lungs of recipient mice until 7 days after transfer (Fig. 4C) .
Taken together, our data show that ␥HV68 latency is a dynamic process in which humoral and cellular immunity contribute to the control of viral reactivation and the prevention of recrudescence. Over time, the virus can escape immune surveillance, leading to the de novo infection of B cells. We propose a model in which gammaherpesviruses persist not only by viral transfer to new B cells during latency, either by cell-to-cell contact or virus release, but also by enhanced intracellular viral replication during periodic reactivation events, thereby increasing the pool of transferrable virus.
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